Metopirone

Metyrapone, the active ingredient in Metopirone, is a 11β‑hydroxylase inhibitor presented as a tablet for oral use. It reduces cortisol synthesis and is employed for diagnostic testing of adrenal function and for treatment of Cushing's syndrome. GNH USA supplies Metopirone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metopirone acts on adrenal steroidogenesis and is used in specific endocrine indications.

Diagnostic testing of adrenal function: helps assess cortisol production capacity during endocrine evaluation. Cushing's syndrome: lowers excess cortisol in patients with endogenous hypercortisolism. ACTH stimulation test: employed to evaluate adrenal responsiveness in specialized diagnostic protocols.

Metyrapone may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Nausea or vomiting - Fatigue or dizziness - Headache - Abdominal discomfort - Mild hypotension - Transient electrolyte changes

Serious or Rare Side Effects: - Acute adrenal insufficiency - Severe hypotension or shock - Allergic reactions including rash or angioedema - Hepatic dysfunction - Hyponatremia or hypokalemia - Persistent hypertension or cardiovascular instability

Use of Metopirone requires careful clinical monitoring and patient education. - Monitor cortisol levels: assess endocrine response before and during therapy. - Assess adrenal function before discontinuation: avoid abrupt withdrawal. - Use with caution in hepatic impairment: dose adjustment may be needed. - Avoid in patients with known hypersensitivity to metyrapone or excipients. - Adjust dose in elderly patients: start low and titrate slowly. - Store at below 25°C: keep in the original pack, protect from moisture.

Metyrapone can alter the activity of several co‑administered drugs, necessitating vigilance.

Major Interactions (Avoid): - Ketoconazole: potent CYP450 inhibition may raise metyrapone concentrations. - Rifampin: strong enzyme induction reduces metyrapone efficacy. - Phenytoin or carbamazepine: induce metabolism, potentially lowering therapeutic effect.

Moderate Interactions (Monitor Closely): - Glucocorticoids: may mask cortisol reduction and complicate assessment. - Antidepressants affecting serotonin: possible additive effects on blood pressure. - Oral contraceptives: hormonal changes may interfere with endocrine testing. - Antihypertensives: monitor blood pressure as metyrapone can cause hypotension.